Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03307577 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris
A Phase 2 study, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT03307577 is a Phase 2 study that has completed, run by Therapeutics. The registered enrollment target is 52 participants.
The verdict
NCT03307577, a Phase 2 study, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris. The purpose of this study is to compare the safety and efficacy of twice daily topical application of UHE-101 cream for 12 weeks to its vehicle cream in subjects with facial acne vulgaris.
Interventions
- DRUG UHE-101 Cream
- OTHER Vehicle Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03307577
The ClinicalTrials.gov registry entry for NCT03307577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which UHE-101 Cream is the first listed.
NCT03307577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03307577 about?
NCT03307577 is a clinical study titled "A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris". UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris. The purpose of this study is to compare the safety and efficacy of twice daily topical application of UHE-101 cream for 12 weeks to its vehicle cream in subjects with facial acne vulgaris.
What is the current status of trial NCT03307577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2017-10-05. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT03307577?
The interventions under investigation include: UHE-101 Cream (DRUG), Vehicle Cream (OTHER).
Who is sponsoring clinical trial NCT03307577?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.